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Abstract
Background: Breathlessness is a debilitating and distressing symptom in a wide variety of diseases and still a
difficult symptom to manage. An integrative review of systematic reviews of non-pharmacological and
pharmacological interventions for breathlessness in non-malignant disease was undertaken to identify the current
state of clinical understanding of the management of breathlessness and highlight promising interventions that
merit further investigation.
Methods: Systematic reviews were identified via electronic databases between July 2007 and September 2009.
Reviews were included within the study if they reported research on adult participants using either a measure of
breathlessness or some other measure of respiratory symptoms.
Results: In total 219 systematic reviews were identified and 153 included within the final review, of these 59
addressed non-pharmacological interventions and 94 addressed pharmacological interventions. The reviews
covered in excess of 2000 trials. The majority of systematic reviews were conducted on interventions for asthma
and COPD, and mainly focussed upon a small number of pharmacological interventions such as corticosteroids
and bronchodilators, including beta-agonists. In contrast, other conditions involving breathlessness have received
little or no attention and studies continue to focus upon pharmacological approaches. Moreover, although there
are a number of non-pharmacological studies that have shown some promise, particularly for COPD, their
conclusions are limited by a lack of good quality evidence from RCTs, small sample sizes and limited replication.
Conclusions: More research should focus in the future on the management of breathlessness in respiratory
diseases other than asthma and COPD. In addition, pharmacological treatments do not completely manage
breathlessness and have an added burden of side effects. It is therefore important to focus more research on
promising non-pharmacological interventions.
Background
Breathlessness is a common symptom which occurs in a
wide range of clinical conditions and affects many indi-
viduals [1]. Some two-thirds of patients experiencing
breathlessness will have a respiratory or cardiac condi-
tion [2]. Breathlessness also often occurs in cancer,
affecting 50-70% of patients [3]. Both frequency and
severity of breathlessness increase towards the end of
life [3-5].
The terms breathlessness and dyspnoea are often used
interchangeably and definitions focus on sensations of
difficulty, discomfort and distress in breathing experi-
enced by those affected [1,3,6], with perhaps the most
authoritative definition coming from the American
Thoracic Society in 1999:
‘...a subjective experience of breathing discomfort that
consists of qualitatively distinct sensations that vary
in intensity. The experience derives from interactions
among multiple physiological, psychological, social,
and environmental factors, and may induce secondary
physiological and behavioural responses’ [1].
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The subjective nature of breathlessness has led to
comparisons with pain as a symptom [3] -and indeed
breathlessness is the most common symptom after pain
for which patients seek medical help [2].
Breathlessness can have a significant impact on daily
living and health-related quality of life for patients and
families [1,3,7-9]. The experience of breathlessness may
markedly reduce patients’ functional ability [1,3,8], and
fear of this symptom can itself lead to activity avoidance
[10,11]. Strong associations between breathlessness and
fatigue have also been noted [1,12,13], which can further
reduce functional ability.
There is a strong relationship between breathlessness
and anxiety or panic [7,8,10,11,14], with the latter often
resulting in patients who experience breathlessness
undergoing emergency hospital admissions. The nature
of the relationship between breathlessness and anxiety
or panic is complex [1,10] and Bailey’s [7] work in
chronic obstructive pulmonary disease suggests that
anxiety may be a consequence of breathlessness, rather
than the reverse. Severe breathlessness may also be asso-
ciated with depression, again the inter-relationship being
complex [14].
Breathlessness is distressing for patients and their
families [7,9,15] and may result in a heavy physical,
social and emotional burden on carers [3,7,8]. Carers of
breathless patients have reported feelings of helpless-
ness, fear, isolation and frustration [3,7,8]. Social isola-
tion is often reported in breathless individuals and their
family members [3,8].
Importantly, breathlessness may have prognostic sig-
nificance. Abidov et al [16] identified increased mortality
in patients with known or suspected cardiac disease in
whom breathlessness was present, while others [13]
comment on the relationship between breathlessness
and poor prognosis in non-heart failure populations.
Associations between breathlessness and mortality have
also been reported in general and elderly population stu-
dies [17,18].
Breathlessness is a common and distressing symptom
in the advanced stages of both malignant and non-
malignant disease. It is characteristic, for example, of
chronic obstructive pulmonary disease (COPD), often
causing marked impairment in activity [19] and confine-
ment to the home [20]. COPD is a progressive, incur-
able illness and a leading cause of disability and
mortality worldwide [21,22]. Despite this, there is evi-
dence that services for people with COPD are poor and
needs (including palliative care needs) are unmet:
indeed, breathlessness in COPD has been described as
‘invisible’, partly because of the lack of attention it
receives from health services [23,24]. Breathlessness is
also a common and devastating symptom in advanced
cancer, with prevalence increasing from referral to
palliative care services (15-55.5%) to the last week of life
(18-79%) and severity reported to be moderate-severe in
10-63% of cases [25]. It causes major impairment in
function and quality of life (QoL) [26]. To date, how-
ever, there is limited evidence that palliative care inter-
ventions have improved breathlessness or that either
medical or nursing care have provided effective assis-
tance to individuals with this symptom [27].
Despite the wide range of conditions that cause dis-
tressing levels of breathlessness, including primary and
secondary cancer, COPD, cystic fibrosis, interstitial lung
disease (ILD) and chronic heart failure (CHF) it is still
very difficult to manage [23,28].
Method
Against this background we conducted an integrative
review of pharmacological and non-pharmacological
interventions for breathlessness within a wide range of
cardiorespiratory diseases. For the purpose of this study,
pharmacological interventions were defined as those
classified as medicinal products under the EU Directive
2001/83/EEC, i.e. any substance or combination of sub-
stances which may be administered to human beings
with a view to making a diagnosis or to restoring, cor-
recting or modifying physiological function in human
beings. Non-pharmacological interventions are those
that are not classified as medicinal products.
This integrative review was undertaken both to provide
a clear account of the current body of work on the subject
and as a preliminary step in developing further interven-
tions for the management of breathlessness and other
respiratory symptoms. Given the large number of systema-
tic reviews available, and the limited clinical utilisation of
many of the interventions found (with the exception of a
few pharmacological interventions such as steroids and
beta-agonists), the decision was taken to focus and limit
the integrative review to only systematic reviews.
We searched the following electronic databases for
systematic reviews of randomised controlled trials,
quasi-experimental trials, and uncontrolled trials where
there were group comparisons of both pharmacological
and non-pharmacological interventions for breathless-
ness in non-malignant disease:
• Cochrane Library (Cochrane Airway Review
Group)
• AMED (1985-June 2007)
• CINAHL (1982-June 2007)
• EMBASE (1988-June 2007)
• Ovid MEDLINE (1950-June 2007)
• PsycINFO (1985-June 2007)
Searching was carried out with a combination of
assigned index (MESH) terms and text words, with
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truncations where appropriate and different spellings
(e.g. dyspnea AND dyspnoea). Between July 2007 and
September 2009, while the data of the review was col-
lated and analysed, regular further searches were carried
out using the key words in order to identify any new
published systematic reviews, adding them to the main
body of the current review.
Databases were searched using the following search
strategy
1. asthma
2. COPD
3. Chronic AND obstruction AND pulmonary AND
disease
4. 2 or 3
5. Heart AND failure
6. Cystic AND fibrosis
7. interstitial MESH lung disease
8. pulmonary AND arterial AND hypertension
9. bronchiectasis
10. 1 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9
11. dyspnea OR dyspnoea
12. difficult AND breath
13. breathlessness
14. short AND breath
15. short of breath
16. 11 OR 12 OR 13 OR 14 OR 15
17. Systematic AND review
18. 10 AND 16 AND 17
Systematic reviews identified in this way were
reviewed independently for inclusion by two of the
authors (AM, RD). Any disagreements were resolved by
discussion. Many reviews did not explicitly measure
breathlessness as an outcome, and for others it was not
the primary outcome. For this reason reviews were eligi-
ble for inclusion in our review if they reported research
on adult participants using not only our primary out-
come measure of breathlessness (e.g. Borg and/or modi-
fied Borg tests, verbal categorical scales, visual analogue
scales), or some other measure of respiratory symptoms
(e.g. including cough, wheeze in a composite score), but
also if they reported other frequently used breathless-
ness related outcome measures such as lung function or
physiological changes (e.g. spirometry, exercise toler-
ance, arterial blood gases, pulse oximetry). Although
these secondary outcomes may act as proxies for breath-
lessness, they do have some limitations. For example,
lung function only moderately relates to the symptom
experience of patients, and exercise tolerance may be as
much a consequence of fatigue as breathlessness. More-
over, many reviews also reported ‘single symptom
scores’, which although included several symptoms,
among them breathlessness too, yielded only a single
composite score. Many reviews also reported upon
improvements in other key outcomes (e.g. survival,
health-related quality of life) that may be linked or influ-
enced by levels of breathlessness, and these have been
included within this review.
Trials of any non-pharmacological intervention were
included, as well as any drug/pharmacological interven-
tion (other than radiotherapy and anti-cancer che-
motherapy), given by any route or in any dose. Reviews
were excluded if they were not available in English, or
were wholly or primarily concerned with the treatment
of children (i.e. aged < 18 years), infections, sleep
apnoea, or cough. They were also excluded if respiratory
symptoms were not included as study outcomes.
Data were extracted by one of the authors (RD) using
a data extraction form designed for the review and was
independently verified by one other author (AM). A
third author (AC) had the role of arbitrator in cases of
disagreement. Data extracted included the nature of the
intervention, the number of trials included in the review,
the aggregated sample, primary and secondary outcome
measures, the condition treated, and the main
conclusions.
Following data extraction, systematic reviews identified
were categorised by condition treated (asthma, COPD,
bronchiectasis, interstitial lung disease, bronchitis,
bronchoconstriction, pulmonary arterial hypertension,
breathlessness (generic), and respiratory failure)
and by treatment type (i.e. non-pharmacological/
pharmacological).
Results
We initially identified 3359 citations, with an addi-
tional 436 resulting from the updated search, giving a
total of 3,795 citations. Of these, 3576 were excluded
based on the title/abstract as they were irrelevant stu-
dies, reviews but not systematic reviews, duplicates,
laboratory studies or individual trials which were
reported in an identified systematic review. From the
219 systematic reviews identified, 66 were further
excluded primarily because they were either paediatric
reviews or reviews of medical devices. Of the 153
reviews that met the inclusion criteria, 59 addressed
non-pharmacological interventions and 94 addressed
pharmacological interventions. A summary of key find-
ings from the review is presented below; further details
of individual systematic reviews are set out in the
Tables presented in Additional Files 1, 2, 3.
Additional file 1 presents data from systematic reviews
of interventions for asthma; Additional file 2 presents
data from systematic reviews of interventions for
chronic obstructive pulmonary disease (COPD), and
Additional file 3 presents data from systematic reviews
of interventions for other respiratory diseases.
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Within this integrative review we have sought to draw
together data from existing systematic reviews. However,
few of the papers included meta-analyses. This was due
to the quality of some of the studies included, variation
of the interventions between and within categories,
variability of the reported data and the provision of
unreported data. It was therefore not possible, for the
purposes of this integrative review, to summarise or
draw conclusions regarding effect sizes and other statis-
tical parameters.
Asthma (non-pharmacological treatments)
A total of 34 systematic reviews were identified. Six
were excluded because they referred only to children.
Of the remaining 28, 26 were published in the Cochrane
Database of Systematic Reviews. Three included data on
breathlessness [29-31], while all others assessed breath-
lessness as part of a composite score of ‘asthma symp-
toms’. In some individual studies these symptom scores
used lung function as a proxy for symptoms, others
included the Asthma Quality of Life Questionnaire that
included symptom categories, while others used the
Asthma Symptom Checklist as an outcome. Further-
more, many of the original trials included a ‘respiratory
symptom’ score, of which breathlessness/dyspnoea was
only part.
Treatments assessed within the reviews included: acu-
puncture [32], breathing exercises/training [30,33,34];
dietary measures [35-39]; Heliox [29,31]; homeopathy
[40]; control of allergens [41,42]; humidity control/ioni-
sers [43,44]; education programs [45-47]; manual ther-
apy[48]; primary care clinics [49]; psychological
interventions [50,51]; individualised care plans [52]; and
non-invasive positive pressure ventilation (NIPPV) [53],
which enhances ventilation by compensating for fatigued
ventilator muscles.
Of those reviews with positive findings, four reported
a single study only [35,49,53,54]. Holloway & Ram [34]
identified seven randomised or quasi-randomised con-
trolled trials of breathing exercises for asthma, conclud-
ing that trends for improvement in QOL were
encouraging, although no firm conclusions could be
drawn, as only 2 of the 7 studies reviewed showed posi-
tive results. Gibson et al [45] concluded from evidence
from 12 RCTs of limited (information only) education
programs that symptom perceptions may improve,
although actual asthma symptoms showed no significant
differences. Yorke et al’s [50] review of 15 RCTs of psy-
chological interventions was unable to draw firm con-
clusions, but following pooling of data, reported two
trials as showing positive effects on QOL after cognitive
behavioural therapy (CBT). Biofeedback also appeared
to have a positive effect on peak expiratory flow (PEF)
in two studies. Gibson et al’s [47] large review of 36
randomised trials concluded that education in asthma
self-management involving self-monitoring by PEF or
symptoms, together with regular review and written
action plans, does improve health outcomes in adults
with asthma. While the systematic reviews show that
the vast majority of non-pharmacological interventions
tested to date have largely been ineffective in relation to
asthma symptoms, some effect has been reported in
trials of calorie controlled diet [35], inspiratory muscle
training [30], manual therapy (particularly massage with
relaxation) [48] and psychoeducational interventions
[50]. The role of Heliox is unclear, as one review
showed no effect on symptoms [29], while another
showed that 3 of 15 trials reviewed had a positive effect
[31]. Selenium supplementation has shown positive
results, but there is only one trial available in the litera-
ture that included a small sample of 24 patients [54].
The conclusions of two trials was that there was no cur-
rent evidence of the effectiveness of the ‘Alexander tech-
nique’ for chronic asthma [55] or that feather bedding
and pillows reduced asthma symptoms compared with
man-made fibres [56].
Asthma (pharmacological treatments)
In all, 69 systematic reviews were identified. Eighteen
were excluded because they referred only to children,
did not specify symptoms as outcomes, or were reviews
of studies of vaccines or comparisons between devices.
Of the 51 reviews included, 50 were accessed via the
Cochrane Database of Systematic Reviews. Seven
included data on breathlessness [57-63] while all others
assessed breathlessness as part of a single score of
‘asthma symptoms’. Again, there was heterogeneity
between systematic reviews in the specific outcomes
measured within these symptom scores.
Treatments included: anti-leukotrienes [64,65]; beta-
agonists (inhaled/non-inhaled) [61-63,66-75]; allergen
immunotherapy [76]; anti-IgE [77]; antibiotics [78]; anti-
cholinergics [57]; azathioprine [79]; beclomethasone
[80-82]; budesonide [83,84]; caffeine [85]; beta-blockers
[58]; chloroquine [86]; corticosteroids (inhaled/non-
inhaled) [59,60,87-91]; cyclosporine [92]; fluticasone
[93-96]; anti-gastro-oesophageal reflux treatment [97];
gold [98]; inhaled/non-inhaled magnesium sulphate
[98,100]; macrolides [101,102]; methotrexate [103]; oxa-
tomide [104]; and tailored interventions based on spu-
tum eosinophils [105].
Many reviews report some level of benefit from or
equivalence between treatments under review. Clearly
steroids (both oral and intramuscular) improve lung
function [60], while long-acting beta agonists (LABA)
with inhaled corticosteroids (ICS) [68] demonstrate
improved outcomes in lung function and symptoms
compared to LABA and antileukotrienes, short-acting
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beta agonists (SABA) [75] or theophylline [74]. Treat-
ments from large scale reviews that report positive
effects most strongly include: allergen immunotherapy
(57 trials) [76], beclomethasone (60 trials) [82], budeso-
nide (43 trials) [84], fluticasone (75 trials) [96],
ICS compared with sodium cromoglycate (25 trials)
[88], LABA (67 trials) [62], and LABA vs. SABA (31
trials) [75].
Small reviews of caffeine (6 trials) [85], inhaled mag-
nesium sulphate (6 trials) [99], intravenous magnesium
sulphate (7 trials) [100], and tailored interventions based
on sputum eosinophils, particularly those with severe
asthma and frequent exacerbations (3 trials) [105] also
suggested therapeutic benefits. Caffeine (taken orally)
has demonstrated a modest, though short-term (up to
4 hours), effect as a bronchodilator.
A number of reviews identified the positive ‘steroid
sparing’ or reduced rescue medication effect of treat-
ments such as Anti-IgE (specifically omalizumab) (14
trials) [88] and LABA [82-84,86] (combined total of 78
trials). One review (67 trials) [62], while reporting the
positive steroid sparing effects of LABA, also raised
some important safety concerns. These concerns related
to a significant increase in asthma related deaths or life
threatening experiences for patients treated with LABA,
mainly among African-American patients and those not
on inhaled corticosteroids. SABA, while generally less
effective than LABA, showed in one review (49 trials)
[70] that regular use of inhaled SABA can decrease
symptoms and rescue medication. A modest effect has
been shown with regards to antileukotrienes [64], aller-
gen immunotherapy [76], cyclosporine [91], gold [98],
and anticholinergics [57]. However, this modest effect in
combination with serious adverse events and/or the
need for close monitoring, make therapeutic options
such as immunotherapy [74], cyclosporine [92] and gold
[98], problematic and inappropriate for clinical use. Two
trials found no evidence to indicate that either colchi-
cines [106] or dapsone [107] were effective in the man-
agement of steroid dependent asthmatic patients.
COPD (non-pharmacological treatments)
A total of 28 systematic reviews were identified. One
was excluded due to lack of focus on respiratory symp-
toms. Fifteen of the remaining reviews were published
in the Cochrane Database of Systematic Reviews.
Twenty also included specific data on breathlessness
[108-123], while all others assessed breathlessness as
part of a composite COPD ‘symptom’ score. Treatments
included: action plans [124]; oxygen/Heliox
[108,110,111,113,121,125]; physical therapy [109]; home
care/hospital at home [126,127]; non-invasive positive
pressure ventilation (NIPPV)/non-invasive ventilatory
support (NIVS) during exercise [119,128]; nutritional
supplements [129]; inhalers [130]; rehabilitation
[112,131]; education/support [120,132]; inspiratory mus-
cle training [114-116]; physical activity [117]; psycholo-
gical interventions [118]; and surgery [122].
The majority of reviews (n = 14) were based on fewer
than 10 trials: six of these had aggregated samples of
more than 150 participants [108-111,119,130]. Positive
effects were reported for breathlessness with domiciliary
oxygen (6 trials [125]), and short term ambulatory oxy-
gen (31 trials [113]). People with COPD are prone to
developing alveolar hypoventilation during exacerba-
tions, which may be contributed to by the administra-
tion of high inspired oxygen concentrations.
Nevertheless, there was no evidence to indicate whether
different oxygen therapies in the pre-hospital setting
have an effect on outcome for people with acute exacer-
bations of COPD [133].
Positive effects were also reported on varied outcomes,
including breathlessness, for NIVS during exercise (7
trials) [119], and lung volume reduction surgery for
end-stage COPD (19 trials) [122], and for outcomes
other than breathlessness for oxygen during training (5
trials) [111] home care/hospital at home (4 trials [126],
7 trials [127]) and individualised action plans (3 trials)
[124]. A large review of pulmonary rehabilitation (31
trials) [112] found that it relieves breathlessness and
fatigue, improves emotional function, and enhances
sense of control; a large review of the chronic care
model in COPD (32 trials) [120] found reductions in
hospitalization rates and emergency/unscheduled visits,
and shorter length of hospital stay, although the result
specifically for breathlessness/symptoms was unclear in
most trials. Four reviews of inspiratory muscle training
concluded that it can improve breathlessness and
health-related quality of life in adults with COPD (19
trials [114], 25 trials [115], 15 trials [116], 15 studies
[123]) and an important addition to pulmonary rehabili-
tation (15 trials) [116]. However, limitations have been
identified within the literature and Shoemaker et al
[123] found that it was unclear whether any improve-
ments were mediated through improved muscle strength
and endurance.
Ram et al [134] reviewed 14 trials concerning NIPPV
for respiratory failure due to exacerbations of COPD. If
applied intermittently and for short periods, NIPPV may
be sufficient to reverse respiratory failure, and it was
found to have a positive effect on a range of outcomes
including mortality, need for intubation, and treatment
failure. The authors conclude that trials demonstrate the
benefits of NIPPV as first line intervention as an adjunct
to usual medical care.
Bausewein et al [28] reviewed non-pharmacological
interventions for breathlessness in COPD, cancer,
chronic heart failure, interstitial lung disease, and motor
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neurone disease. Strong evidence was identified to show
that neuro-electrical muscle stimulation (NMES) and
chest wall vibration (CWV) could relieve breathlessness
in COPD, and there was moderate evidence in favour of
walking aids in COPD and breathing training in studies
of mixed cardio-pulmonary disease and COPD. The
authors found only low strength evidence of relief from
breathlessness with acupuncture or acupressure, and no
evidence for the effect of music. They noted that only a
few studies included participants with conditions other
than COPD. Insufficient data were available to evaluate
evidence for a range of other interventions, including
relaxation, counselling and support, case management
and psychotherapy.
COPD (pharmacological treatments)
In all, 22 systematic reviews were identified. Three were
excluded (lack of focus on respiratory symptoms/non-
intervention studies). Two of the remaining 19 reviews
were located from sources other than the Cochrane
Database. Sixteen included data on breathlessness
[135-149] while the others assessed breathlessness as
part of a single symptom score. Treatments included:
bronchodilators [135,140,141,144,147,148]; LABA and
LABA in addition to steroids [136,142,149]; vaccines
[137,139]; inhaled/non-inhaled corticosteroids
[143,146,150]; SABA [138,145]; methylxanthines [151];
and mucolytics [152].
Seven reviews were based on evidence from fewer
than 10 trials [135,136,138-140,147,151]. One of these
referred to an aggregated sample of fewer than 150 par-
ticipants [138]. In one review the size of the aggregated
sample was unclear [148]. Positive conclusions were
drawn in respect of some aspect of intervention(s) for
COPD in over half of the reviews, including: combined
corticosteroid and LABA in a single inhaler (6 trials)
[136]; influenza vaccine (6 trials) [137]; ICS (47 trials)
[150]; ipratroprium vs. LABA (7 trials) [140]; LABA (23
trials) [142]; mucolytic agents (although their effect was
small) (26 trials) [152]; oral corticosteroids (OCS) (24
trials) [143]; oral theophylline with a modest effect on
lung function but largely ineffective in relation to
breathlessness (20 trials) [144]; SABA (13 trials) [145];
systemic corticosteroids (10 trials) [146]; tiatropium (9
trials) [147]; bronchodilators, i.e. b-agonists, anti-choli-
nergics and theophyllines (33 trials) [148]; and LABA
(12 trials) [149]. A large review of 47 trials (13,139
patients) [150] showed that ICS used for 2-6 months
resulted in small symptom improvements, while use for
more than 6 months had limited effect on symptoms.
Jennings et al [153] reviewed 18 trials concerning the
use of opioids for dyspnoea in both cancer and non-
malignant conditions (e.g. chronic heart failure, COPD,
interstitial lung disease, pulmonary fibrosis), concluding
that opioids have a positive effect on the sensation of
breathlessness. Data did not support the use of nebu-
lised morphine in the management of breathlessness.
Bronchiectasis (non-pharmacological treatments)
Searches identified three systematic reviews. One of
these was excluded because it focussed on surgical inter-
vention only. The remaining reviews (both from the
Cochrane Database) featured nurse specialist care (1
trial) [154] and physical training (2 trials) [155]. Bradley
et al [155] included data on breathlessness. Both reviews
were based on aggregated samples of less than 80 parti-
cipants. French et al [154] reviewed one trial of nurse-
led care (no significant changes in outcome measures or
significant difference compared to doctor-led care).
Bradley et al [156] included two trials of physical ther-
apy, concluding that inspiratory muscle training
improved endurance exercise capacity.
Bronchiectasis (pharmacological treatments)
Searches identified four systematic reviews from the
Cochrane database (2 trials [156]; 2 trials [157]; 3 trials
[158]; 9 trials [159]) that found evidence of effectiveness.
Two reviews [156,157] were based on samples of more
than 54; in a third review [158] it was not possible to
determine the size of the aggregated sample. One review
[156] included data on breathlessness. Wills & Green-
stone [156] concluded that dry powder mannitol was
shown to improve tracheobronchial clearance in bronch-
iectasis. Ram et al [157] found that ICS may improve
lung function in bronchiectasis, but that larger trials
were required to guide practice. Evans et al [159] found
a small benefit from prolonged antibiotic use to inter-
rupt the cycle of bacterial colonisation, inflammatory
change and progressive lung damage, but also advocated
further, more powerful trials. Crockett et al [158] con-
cluded that there was insufficient evidence to evaluate
mucolytics for bronchiectasis. There were also seven
systematic reviews that found no evidence of effective-
ness of pharmacological treatments in the management
of bronchiectasis: for oral methylxanthines [160]; LABAs
[161]; SABAs [162]; anticholinergic therapy [163]; leuko-
triene receptor antagonists [164]; oral steroids [165];
and pneumococcal vaccines [166].
Pulmonary sarcoidosis, pulmonary fibrosis, interstitial
lung disease
Five systematic reviews (Cochrane Database) were con-
sidered, three of which included data on breathlessness
[167-169]. Paramothayan et al [170] reviewed 13 trials
of corticosteroids for pulmonary sarcoidosis, concluding
that oral steroids may be of use in some circumstances.
Paramothayan et al [168] further reviewed five trials and
found limited evidence to support the use of
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immunosuppressive and cytotoxic therapy for this con-
dition. Davis et al [167] reviewed three trials and found
little to justify routine use of non-corticosteroid agents
for idiopathic pulmonary fibrosis (IPF), and Richeldi
et al [171] found no evidence for an effect of corticos-
teroid treatment in patients with IPF. Polosa et al [169]
reviewed a single small trial of nebulised morphine in
interstitial lung disease (six participants), which reported
no improvement in maximal exercise performance or
reduction in breathlessness during exercise.
Chronic bronchitis
Staykova et al [172] reviewed nine trials of prophylactic
antibiotic use in chronic bronchitis/COPD, concluding
that this treatment does significantly reduce days of ill-
ness due to exacerbations. Routine use is not recom-
mended due to concerns about antibiotic resistance and
it is noted that available data are over 30 years old.
Exercise-induced broncho-constriction
Three reviews were considered from the Cochrane Data-
base [173-175]. Spooner et al [173] (24 trials) compared
the effects of inhaled mast-cell stabilisers with single dose
SABAs or anticholinergics prior to exercise, concluding
that all provided relief against broncho-constriction. Over-
all, SABAs were more effective than mast-cell stabilisers,
which were in turn more effective than anticholinergics.
Spooner et al [174] (20 trials) concluded that a single dose
of a mast-cell stabiliser (nedocromil sodium) before exer-
cise reduces the severity and duration of exercise-induced
bronchoconstriction. Kelly et al [175] (8 trials) found no
difference between the effect of nedocromil sodium and
sodium cromoglycate on lung function following exercise.
Pulmonary arterial hypertension (PAH)
Three reviews were considered from the Cochrane Data-
base [176-178]. All included data on breathlessness. Liu
& Chen [176] reviewed five trials that evaluated
endothelin receptor antagonists (ERAs), finding that, in
conjunction with conventional therapy, their use
improved Borg dyspnoea scores and exercise capacity
amongst patients with idiopathic PAH. Paramothayan
et al [177] reviewed nine trials that considered the effects
of prostacyclin with conventional therapy, identifying
some short-term benefits (e.g. on exercise capacity).
Kanthapillai et al [178] reviewed four trials that consid-
ered the effects of the vasodilator sildenafil, concluding
that the benefits observed in small trials required further
validation in more adequately-sized studies.
Cystic fibrosis
Reid et al [179] reviewed two trials concerning the effect
of inspiratory muscle training (IMT) on patients with
cystic fibrosis. Individual study results were found to be
inconclusive for improvement in inspiratory muscle
strength, though one study demonstrated improvement
in inspiratory muscle strength endurance. The authors
concluded that the benefit of IMT in cystic fibrosis for
outcomes in inspiratory muscle strength was supported
by weak evidence, but that its impact on exercise capa-
city, dyspnoea and quality of life was unclear.
Discussion
Improvements are needed in the management of breath-
lessness in both malignant and non-malignant condi-
tions. Asthma affects an approximately 5.2 million people
in the UK [180], with an estimated 42% of them facing
significant challenges in their daily lives due to breath-
lessness [181]. COPD is projected to rank as the world’s
third leading cause of death by 2030 [182], while the
reported frequency of breathlessness in cancer varies
depending upon the stage of disease [183]. As disease
becomes advanced, so the incidence of breathlessness
tends to increase [3-5]. In advanced cardiorespiratory dis-
ease, for example, refractory breathlessness is described
as a ‘devastating’ symptom with few effective palliative
options [184]. Solano et al [185] found that breathless-
ness was one of three ‘particularly universal’ symptoms
(with pain and fatigue) that affected more than 50% of
patients with far advanced cancer, AIDS, heart disease,
COPD and renal disease. Despite this high prevalence
and level of severity, breathlessness and other related
symptoms are under-assessed and under-treated [185].
Our review of systematic reviews suggests that while
breathlessness in some non-malignant conditions has
been intensively addressed, mostly through a small
range of mainly pharmacological approaches, there are
other conditions that have received little or no attention.
The majority of systematic reviews we identified have
been conducted on interventions for asthma and COPD.
In comparison, no other category of disease produced
more than six reviews for pharmacological and non-
pharmacological approaches combined.
The emphasis in systematic reviews of pharmacologi-
cal interventions for asthma is clearly on beta-agonists
and corticosteroids, with the use of these for relevant
asthma-related conditions and in combination with
other appropriate pharmacological agents receiving wide
support [59,60,62,69,71-75,88,91,96], though with some
safety concerns [62]. Reviews that address the ‘steroid-
sparing’ or rescue medication reduction features of var-
ious approaches to the pharmacological treatment of
asthma are an important sub-group of studies, given the
known side-effect profile of this class of drugs
[62,64-66,68,70-73,75,77,82-84,87,88,92,93,96,98,103-
105].
Systematic reviews of non-pharmacological interven-
tions for asthma are limited by a lack of good quality
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evidence from randomised controlled trials. The largest
review of non-pharmacological interventions, which
assessed the effects of asthma self-management pro-
grammes with regular health practitioner review did,
however, conclude that this approach, particularly when
it includes training to use written action plans to adjust
medication, can improve health outcomes in adults with
asthma [47].
Bronchodilators, including beta-agonists, are the focus
for the majority of reviews of pharmacological interven-
tions for COPD. Positive results were identified among
these, and for a number of other agents, including corti-
costeroids, vaccine, and mucolytics, although balancing
potential benefits against known risks remains impor-
tant. Non-pharmacological interventions with positive
outcomes appear to be more established in COPD than
in asthma, at least as far as number of trials is con-
cerned. In a number of cases successful interventions
were broadly rehabilitative in nature: home care from
outreach nursing programmes was shown to have bene-
fits in terms of survival and health related quality of life
[127], hospital at home was an effective option for some
patients attending emergency departments with an acute
exacerbation of their condition [127], pulmonary rehabi-
litation was found to relieve breathlessness and fatigue,
improve emotional function, and enhance sense of con-
trol [112], and use of two or more components of the
chronic care model resulted in reduced hospitalisations
and emergency visits and reduced length of hospital stay
[120].
Benefits for a number of outcomes in COPD, includ-
ing breathlessness, were also found to be provided by
IMT within four studies [114-116,124], though one
study found that it was unclear whether any such
improvement is mediated through improved muscle
strength and endurance [123]. Inspiratory muscle train-
ing was also found to improve breathing, exercise capa-
city and quality of life in Bradley et al [155] review of
physical training for bronchiectasis, although a similar
review in patients with cystic fibrosis showed inconclu-
sive results [179].
In contrast to reviews of asthma treatments, data on
breathlessness were included in the majority of reviews
of interventions for COPD, both pharmacological and
non-pharmacological. Given the distressing nature of
breathlessness from the point of view of those who
experience it, it is surprising that more studies do not
include a specific measure of this symptom. Breathless-
ness and dyspnoea characterise a range of qualitatively
distinct experiences of breathing discomfort, and there-
fore, outcome measures should arguably take account of
patients’ perceptions and the language patients use to
describe the symptom [186-188]. However, as Bausewein
et al [189] point out, no one of the many assessment
tools available is comprehensive enough as a single
instrument to measure the sensation of breathlessness,
its effect on quality of life, and response to treatment.
Indeed, this review suggests that the research may
emphasise physiological lung changes rather than the
subjective experience of a very distressing symptom. It
also suggests that findings may reflect lung function
rather than symptom experience or symptom distress.
A considerable proportion of the original trials
reported in the systematic reviews included either proxy
measures for breathlessness (e.g. lung function), used
unvalidated measures or used single composite scores
for ‘respiratory symptoms’ that differed both within and
between systematic reviews, so providing only indica-
tions for the level of improvement related to breathless-
ness per se. This is quite problematic as the ‘validity’
and sensitivity of such methods to accurately measure a
complex, subjective symptom experience is questionable
and can lead to biases, as there is a significant issue
with the interpretation of the data, which clinicians
often find confusing. Future research should address
these measurement issues and use data from validated,
patient-reported outcome measures (PROMS) of breath-
lessness as the primary outcome (e.g. the MRC dys-
pnoea scale [190] or Dyspnoea-12 [188]), in adequately
powered trials.
With the exception of research into treatments for
asthma and COPD, the majority of intervention studies,
as reflected in our review, continue to focus on pharma-
cological approaches. We have included two reviews of
non-pharmacological interventions for bronchiectasis,
but in all other disease categories we found no further
examples. More research should focus in the future on
the management of breathlessness in respiratory diseases
other than asthma and COPD.
As pharmacological treatments do not completely
manage breathlessness and they have the added burden
of side effects, it seems imperative that non-pharmacolo-
gical interventions are seen as appropriate complemen-
tary interventions to standard pharmacological
management, or even an alternative method in selected
patients. Despite good evidence from the literature,
many non-pharmacological interventions have not
become mainstream and are not used in the rehabilita-
tion of patients with respiratory diseases. New ways of
thinking about evaluation research, and new combina-
tions of pharmacological and non-pharmacological
interventions may be needed for symptoms like breath-
lessness that continue to impose a heavy burden of dis-
tress across a wide range of disease types.
There are also a number of non-pharmacological stu-
dies that have shown some promise, although conclu-
sions are difficult due to the small sample sizes they
have used and limited replication. Such interventions
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include oxygen, self-management approaches, breathing
exercises, use of fans, acupuncture/acupressure, calorie
controlled diet, selenium supplementation, approaches
to reduce anxiety and panic, or those interventions that
may be theoretically useful but for which no studies
have been carried out so far (e.g. Alexander technique
or other complementary therapies). Future research
should focus on such promising approaches and provide
a good evidence-base for practice.
Conclusions
While the reviews have covered in excess of 2,000 trials,
the management of breathlessness remains far from
ideal and patients suffer unnecessarily, particularly in
the advanced stages of their illness. The development of
society guidelines and agreed standards of care should
provide a good way for clinicians to navigate across the
diversity of potential treatments for breathlessness. Such
guidelines should incorporate both pharmacological and
non-pharmacological interventions where appropriate.
More research is needed in areas of potential benefit,
with particular emphasis in the accurate and reliable
assessment of breathlessness and in ways that could
improve the quality of life as well as health care provi-
sion for patients experiencing this distressing symptom.
The recent development of clinical guidelines for the
management of breathlessness/dyspnea provides some
direction for the clinicians in this complex area of symp-
tom management [191].
Additional material
Additional file 1: Table 1. Systematic reviews of interventions for
asthma. List of all the studies reviewed under asthma and the data
reported in the reviews.
Additional file 2: Table 2. Systematic reviews of interventions for
chronic obstructive pulmonary disease (COPD). List of all the studies
reviewed under COPD and the data reported in the reviews.
Additional file 3: Table 3. Systematic reviews of interventions for
other respiratory diseases. List of all the studies reviewed under other
respiratory diseases and the data reported in the reviews.
Acknowledgements
This review was partly funded by The Breathlessness Research Charitable
Trust, UK and the National Cancer Research Institute.
Author details
1Faculty of Health Sciences, University of Southampton, Highfield,
Southampton, SO17 1BJ, UK. 2School of Nursing, Midwifery & Social Work,
University of Manchester, Manchester M13 9PL, UK. 3Department of
Translational Medicine, University of Manchester, Manchester, UK & Johns
Hopkins Asthma and Allergy Center, Boston, USA.
Authors’ contributions
Conception of study, development of protocol, study coordination: AM;
Searches: RD, RW; Data Extraction, Data Verification, Arbitration: AM, RD, RW,
AC, JS; Data Synthesis/Analysis: CB, RW, AM, AC, JS; Data discussions: All
authors; Drafting paper: AM, RW, CB. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 October 2010 Accepted: 9 December 2010
Published: 9 December 2010
References
1. American Thoracic Society: Dyspnea: mechanisms, assessment, and
management: a consensus statement. Am J Respir Crit Care Med 1999,
159:321-340.
2. Karnani NG, Reisfield GM, Wilson GR: Evaluation of chronic dyspnea. Am
Fam Physician 2005, 71(8):1529-1537.
3. Cox C: Non-pharmacological treatment of breathlessness. Nurs Standard
2002, 16(24):33-36.
4. Luddington L, Cox S, Higginson I, Livesley B: The need for palliative care
for patients with non-cancer diseases: a review of the evidence. Int J
Palliat Nurs 2001, 7(5):221-226.
5. Rawlinson F: Dyspnoea and cough. Eur J Palliat Care 2000, 7(5):161-164.
6. Cranston JM, Crockett A, Currow D: Oxygen therapy for dyspnoea in
adults. Cochrane Database of Systematic Reviews 2008, CD004769.
7. Bailey PH: The dyspnea-anxiety-dyspnea cycle-COPD patients’ stories of
breathlessness: “it’s scary/when you can’t breathe”. Qual Health Res 2004,
14(6):760-778.
8. Harris S: COPD and coping with breathlessness at home: a review of the
literature. Br J Community Nur 2007, 12(9):411-415.
9. Seamark DA, Blake SD, Seamark CJ: Living with severe chronic obstructive
pulmonary disease: perceptions of patients and their carers. Pallit Med
2004, 18(7):619-625.
10. Simon NM, Weiss AM, Kradin R, Evans KC, Reese HE, Otto MW,
Oppenheimer JE, Smoller JW, Zalta A, Worthington III JJ, Pollack MH: The
relationship of anxiety disorders, anxiety sensitivity and pulmonary
dysfunction with dyspnea-related distress and avoidance. J Nerv Ment Dis
2006, 194(12):951-957.
11. Smoller JW, Pollack MH, Otto MW, Rosenbaum JF, Kradin RL: Panic anxiety,
dyspnea, and respiratory disease. Theoretical and clinical considerations.
Am J Respir Crit Care Med 1996, 154(1):6-17.
12. Clark AL, Sparrow JL, Coats AJS: Muscle fatigue and dyspnoea in chronic
heart failure: two sides of the same coin? Eur Heart J 1995, 16(1):49-52.
13. Witte KA, Clark AL: Dyspnoea versus fatigue: additional prognostic
information from symptoms in chronic heart failure? Eur J of Heart Failure
2008, 10(12):1224-1228.
14. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM,
Hanania NA: Anxiety and depression in COPD. Chest 2008, 134:43S-56S.
15. Roberts DK, Thorne SE, Pearson C: The experience of dyspnoea in late
stage cancer: patients’ and nurse perspectives. Cancer Nurs 1993,
16(4):310-320.
16. Abidov A, Rozanski A Hachamovitch R, Hayes SW, Aboul-Enein F, Cohen I,
Friedman JD Germano G, Berman DS: Prognostic significance of dyspnea
in patients referred for cardiac stress testing. N Eng J Med 2005,
353:1889-1898.
17. Frostad A, Soyseth V, Haldorsen T, Andersen A, Gulsvik A: Respiratory
symptoms and long-term cardiovascular mortality. Respir Med 2007,
101(11):2289-2296.
18. Tessier JF, Nejjari C, Letenneur L, Filleul L, Marty ML, Barberger Gateau P,
Dartigues JF: Dyspnea and 8-year mortality among elderly men and
women: the PAQUID cohort study. Eur J of Epidemiology 2001, 17:223-229.
19. Jones PW: Activity limitation and quality of life in COPD. J COPD 2007,
4:273-278.
20. Donaldson GC, Wilkinson TMA, Hurst JR, Perera WR, Wedzicha JA:
Exacerbations and time spent outdoors in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2005, 171:446-452.
21. Murray CJL, Lopez AD: Alternative projections of mortality and disability
by cause 1990-2020: global burden of disease study. Lancet 1997,
349:1498-1504.
22. Lopez AD, Murray CCJL: The global burden of disease, 1990-2020. Nat
Med 1998, 4(11):1241-1243.
Bailey et al. BMC Pulmonary Medicine 2010, 10:63
http://www.biomedcentral.com/1471-2466/10/63
Page 9 of 13
23. Gysels M, Higginson IJ: Access to Services for Patients with Chronic
Obstructive Pulmonary Disease: The Invisibility of Breathlessness. J Pain
& Symptom Manage 2008, 36:451-460.
24. Gore JM, Brophy CJ, Greenstone MA: How well do we care for patients
with end stage chronic obstructive pulmonary disease (COPD)? A
comparison of palliative care and quality of life in COPD and lung
cancer. Thorax 2000, 55:1000-1006.
25. Ripamonti C, Fusco F: Respiratory problems in advanced cancer. Support
Care Cancer 2001, 10:204-216.
26. Bruera E, Schmitz B, Pither J, Neuman CM, Hanson J: The frequency and
correlates of dyspnea in patients with advanced cancer. J Pain Symptom
Manage 2006, 19:357-362.
27. Booth S, Moosavi SH, Higginson IJ: The etiology and management of
intractable breathlessness in patients with advanced cancer: a
systematic review of pharmacological therapy. Nature Clin Pract 2008, 5(2
February):90-100.
28. Bauswein C, Booth S, Gysels M, Higginson IJ: Non-pharmacological
interventions for breathlessness in advanced stages of malignant and
non-malignant diseases (Review). Cochrane Database of Systematic Reviews
2008, CD005623.
29. Rodrigo G, Pollack C, Rodrigo C, Rowe BH: Heliox for nonintubated acute
asthma patients. Cochrane Database of Systematic Reviews 2006, CD002884.
30. Ram FSF, Wellington SR, Barnes NC: Inspiratory muscle training for
asthma. Cochrane Database of Systematic Reviews 2003, CD003792.
31. Ho AM-H, Lee A, Karmaker MK, Dion PW, Chung DC, Contardi L-A H: Heliox
vs air-oxygen mixtures for the treatment of patients with acute asthma -
A systematic review. Chest 2003, 123:882-890.
32. McCarney RW, Brinkhaus B, Lasserson TJ, Linde K: Acupuncture for chronic
asthma. Cochrane Database of Systematic Reviews 2003, CD000008.
33. Ram FSF, Robinson SM, Black PN, Picot J: Physical training for asthma.
Cochrane Database of Systematic Reviews 2005, CD001116.
34. Holloway E, Ram FSF: Breathing exercises for asthma. Cochrane Database
of Systematic Reviews 2004, CD001277.
35. Cheng J, Pan T, Ye GH, Liu Q: Calorie controlled diet for chronic asthma.
Cochrane Database of Systematic Reviews 2003, CD004674.
36. Thien FCK, De Luca S, Woods R, Abramson MJ: Dietary marine fatty acids
(fish oil) for asthma in adults and children. Cochrane Database of
Systematic Reviews 2002, CD001283.
37. Ram FSF, Ardern KD: Dietary salt reduction or exclusion for allergic
asthma. Cochrane Database of Systematic Reviews 2004, CD000436.
38. Ram FS, Ardern KD: Tartrazine exclusion for allergic asthma. Cochrane
Database of Systematic Reviews 2001, CD000460.
39. Ram FSF, Rowe BH, Kaur B: Vitamin C supplementation for asthma.
Cochrane Database of Systematic Reviews 2004, CD000993.
40. McCarney RW, Linde K, Lasserson TJ: Homeopathy for chronic asthma.
Cochrane Database of Systematic Reviews 2004, CD000353.
41. Gotzsche PC, Johansen HK, Schmidt LM, Burr ML: House dust mite control
measures for asthma. Cochrane Database of Systematic Reviews 2004,
CD001187.
42. Kilburn S, Lasserson TJ, McKean M: Pet allergen control measures for
allergic asthma in children and adults. Cochrane Database of Systematic
Reviews 2001, CD002989.
43. Singh M, Bara A, Gibson P: Humidity control for chronic asthma. Cochrane
Database of Systematic Reviews 2002, CD003563.
44. Blackhall K, Appleton S, Cates CJ: Ionisers for chronic asthma. Cochrane
Database of Systematic Reviews 2003, CD002986.
45. Gibson PG, Powell H, Coughlan J, Wilson AJ, Hensley MJ, Abramson M,
Bauman A, Walters EH: Limited (information only) patient education
programs for adults with asthma. Cochrane Database of Systematic Reviews
2002, CD001005.
46. Powell H, Gibson PG: Options for self-management education for adults
with asthma. Cochrane Database of Systematic Reviews 2002, CD004107.
47. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P,
Bauman A, Hensley MJ, Walters EH: Self-management education and
regular practitioner review for adults with asthma. Cochrane Database of
Systematic Reviews 2002, CD001117.
48. Hondras MA, Linde K, Jones AP: Manual therapy for asthma. Cochrane
Database of Systematic Reviews 2005, CD001002.
49. Ram FSF, Jones A, Fay JK: Primary care based clinics for asthma. Cochrane
Database of Systematic Reviews 2002, CD003533.
50. Yorke J, Fleming SL, Shuldham CM: Psychological interventions for adults
with asthma. Cochrane Database of Systematic Reviews 2006, CD002982.
51. Smith J, Mugford M, Holland R, Candy B, Noble MJ, Harrison BDW,
Koutantji M, Upton C, Harvey I: A systematic review to examine the
impact of psycho-educational interventions on health outcomes and
costs in adults and children with difficult asthma. Health Technol Assess
2005, 9(23):iii-iv, 1-167.
52. Toelle BG, Ram FSF: Written individualised management plans for asthma
in children and adults. Cochrane Database of Systematic Reviews 2004,
CD002171.
53. Ram FSF, Wellington SR, Rowe B, Wedzicha JA: Non-invasive positive
pressure ventilation for treatment of respiratory failure due to severe
acute exacerbations of asthma. Cochrane Database of Systematic Reviews
2005, CD004360.
54. Allam MF, Lucena RA: Selenium supplementation for asthma. Cochrane
Database of Systematic Reviews 2004, CD003538.
55. Dennis J, Cates CJ: Alexander technique for chronic asthma. Cochrane
Database of Systematic Reviews 2000, CD000995.
56. Campbell F, Jones K, Gibson P: Feather versus non-feather bedding for
asthma. Cochrane Database of Systematic Reviews 2000, CD002154.
57. Westby M, Benson M, Gibson P: Anticholinergic agents for chronic
asthma in adults. Cochrane Database of Systematic Reviews 2004,
CD003269.
58. Salpeter S, Ormiston T, Salpeter E, Wood-Baker R: Cardioselective beta-
blockers for reversible airway disease. Cochrane Database of Systematic
Reviews 2002 2002, CD002992.
59. Manser R, Reid D, Abramson M: Corticosteroids for acute severe asthma
in hospitalised patients. Cochrane Database of Systematic Reviews 2001,
CD001740.
60. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW:
Corticosteroids for preventing relapse following acute exacerbations of
asthma. Cochrane Database of Systematic Reviews 2001, CD000195.
61. Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA Jr, Rowe BH:
Intravenous beta2-agonists for acute asthma in the emergency
department. Cochrane Database of Systematic Reviews 2001, CD002988.
62. Walters EH, Gibson PG, Lasserson TJ, Walters JAE: Long-acting beta2-
agonists for chronic asthma in adults and children where background
therapy contains varied or no inhaled corticosteroid. Cochrane Database
of Systematic Reviews 2007, CD001385.
63. Richter B: Long- and Short-Acting Inhaled Beta~2-Agonists: Do Benefit-
Risk-Ratios Differ in the Treatment of Bronchial Asthma and COPD? Z
Allg Med 2006, 82(6):253-258.
64. Ducharme F, Schwartz Z, Kakuma R: Addition of anti-leukotriene agents to
inhaled corticosteroids for chronic asthma. Cochrane Database of
Systematic Reviews 2004 2004, CD003133.
65. Ducharme FM, Di Salvio F: Anti-leukotriene agents compared to inhaled
corticosteroids in the management of recurrent and/or chronic asthma
in adults and children. Cochrane Database of Systematic Reviews 2004,
CD002314.
66. Ni Chroinin M, Greenstone IR, Ducharme FM: Addition of inhaled long-
acting beta2-agonists to inhaled steroids as first line therapy for
persistent asthma in steroid-naive adults. Cochrane Database of Systematic
Reviews 2004, CD005307.
67. Parameswaran K, Belda J, Rowe BH: Addition of intravenous
aminophylline to beta2-agonists in adults with acute asthma. Cochrane
Database of Systematic Reviews 2000, CD002742.
68. Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X,
Ducharme FM: Combination of inhaled long-acting beta2-agonists and
inhaled steroids versus higher dose of inhaled steroids in children and
adults with persistent asthma. Cochrane Database of Systematic Reviews
2005, CD005533.
69. Camargo CA Jr, Spooner CH, Rowe BH: Continuous versus intermittent
beta-agonists for acute asthma. Cochrane Database of Systematic Reviews
2003, CD001115.
70. Walters EH, Walters J, Gibson P, Jones PW: Inhaled short acting beta2-
agonist use in chronic asthma: regular versus as needed treatment.
Cochrane Database of Systematic Reviews 2003, CD001285.
71. Gibson PG, Powell H, Ducharme F: Long-acting beta2-agonists as an
inhaled corticosteroid-sparing agent for chronic asthma in adults and
children. Cochrane Database of Systematic Reviews 2005, CD005076.
Bailey et al. BMC Pulmonary Medicine 2010, 10:63
http://www.biomedcentral.com/1471-2466/10/63
Page 10 of 13
72. Ducharme FM, Lasserson TJ, Cates CJ: Long-acting beta2-agonists versus
anti-leukotrienes as add-on therapy to inhaled corticosteroids for
chronic asthma. Cochrane Database of Systematic Reviews 2006, CD003137.
73. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X,
Ducharme FM: Long-acting beta2-agonists versus placebo in addition to
inhaled corticosteroids in children and adults with chronic asthma.
Cochrane Database of Systematic Reviews 2005, CD005535.
74. Shah L, Wilson AJ, Gibson PG, Coughlan J: Long-acting beta2-agonists
versus theophylline for maintenance treatment of asthma. Cochrane
Database of Systematic Reviews 2003, CD001281.
75. Walters EH, Walters JAE, Gibson PW: Regular treatment with long acting
beta agonists versus daily regular treatment with short acting beta
agonists in adults and children with stable asthma. Cochrane Database of
Systematic Reviews 2002, CD003901.
76. Abramson MJ, Puy RM, Weiner JM: Allergen immunotherapy for asthma.
Cochrane Database of Systematic Reviews 2003, CD001186.
77. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH: Anti-IgE for
chronic asthma in adults and children. Cochrane Database of Systematic
Reviews 2006, CD003559.
78. Graham V, Lasserson TJ, Rowe BH: Antibiotics for acute asthma. Cochrane
Database of Systematic Reviews 2001, CD002741.
79. Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH: Azathioprine as an oral
corticosteroid sparing agent for asthma. Cochrane Database of Systematic
Reviews 2003, CD003270.
80. Adams N, Bestall J, Jones P: Beclomethasone at different doses for
chronic asthma. Cochrane Database of Systematic Reviews 1999, CD002879.
81. Adams N, Bestall JM, Jones PW: Beclomethasone versus budesonide for
chronic asthma. Cochrane Database of Systematic Reviews 2000, CD003530.
82. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW: Beclomethasone
versus placebo for chronic asthma. Cochrane Database of Systematic
Reviews 2005, CD002738.
83. Adams N, Bestall J, Jones P: Budesonide at different doses for chronic
asthma. Cochrane Database of Systematic Reviews 2000, CD003271.
84. Adams N, Bestall J, Jones PW: Budesonide versus placebo for chronic
asthma in children and adults. Cochrane Database of Systematic Reviews
1999, CD003274.
85. Bara AI, Barley EA: Caffeine for asthma. Cochrane Database of Systematic
Reviews 2001, CD001112.
86. Dewey A, Dean T, Bara A, Lasserson TJ, Walters EH: Chloroquine as a
steroid sparing agent for asthma. Cochrane Database of Systematic Reviews
2003, CD003275.
87. Powell H, Gibson PG: High dose versus low dose inhaled corticosteroid
as initial starting dose for asthma in adults and children. Cochrane
Database of Systematic Reviews 2003.
88. Guevara JP, Ducharme FM, Keren R, Nihtianova S, Zorc J: Inhaled
corticosteroids versus sodium cromoglycate in children and adults with
asthma. Cochrane Database of Systematic Reviews 2006, CD003558.
89. Edmonds ML, Camargo CA Jr, Brenner BE, Rowe BH: Inhaled steroids for
acute asthma following emergency department discharge. Cochrane
Database of Systematic Reviews 2000, CD002316.
90. Mash B, Bheekie A, Jones PW: Inhaled versus oral steroids for adults with
chronic asthma. Cochrane Database of Systematic Reviews 2001, CD002160.
91. Taramarcaz P, Gibson PG: Intranasal corticosteroids for asthma control in
people with coexisting asthma and rhinitis. Cochrane Database of
Systematic Reviews 2003, CD003570.
92. Evans DJ, Cullinan P, Geddes DM, Walters EH, Milan SJ, Jones PW:
Cyclosporin as an oral corticosteroid sparing agent in stable asthma.
Cochrane Database of Systematic Reviews 2000, CD002993.
93. Adams NP, Bestall JC, Jones PW, Lasserson TJ, Griffiths B, Cates CJ:
Fluticasone at different doses for chronic asthma in adults and children.
Cochrane Database of Systematic Reviews 2005, CD003534.
94. Lasserson TJ, Cates CJ, Jones A-B, Steele EH, White J: Fluticasone versus
HFA-beclomethasone dipropionate for chronic asthma in adults and
children. Cochrane Database of Systematic Reviews 2006, CD005309.
95. Adams N, Bestall JM, Lasserson TJ, Jones PW: Fluticasone versus
beclomethasone or budesonide for chronic asthma in adults and
children. Cochrane Database of Systematic Reviews 2005, CD002310.
96. Adams NP, Bestall JC, Lasserson TJ, Jones PW, Cates CJ: Fluticasone versus
placebo for chronic asthma in adults and children. Cochrane Database of
Systematic Reviews 2005, CD003135.
97. Gibson PG, Henry RL, Coughlan JL: Gastro-oesophageal reux treatment for
asthma in adults and children. Cochrane Database of Systematic Reviews
2003, CD001496.
98. Evans DJ, Cullinan P, Geddes DM, Walters EH, Milan SJ, Jones PW: Gold as
an oral corticosteroid sparing agent in stable asthma. Cochran Database
of Systematic Reviews 2000, CD002985.
99. Blitz M, Blitz S, Beasely R, Diner BM, Hughes R, Knopp JA, Rowe BH: Inhaled
magnesium sulfate in the treatment of acute asthma. Cochrane Database
of Systematic Reviews 2005, CD003898.
100. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr: Magnesium
sulfate for treating exacerbations of acute asthma in the emergency
department. Cochrane Database of Systematic Reviews 2000, CD001490.
101. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG: Macrolides for
chronic asthma. Cochrane Database of Systematic Reviews 2005, CD002997.
102. Evans DJ, Cullinan P, Geddes DM, Walters EH, Milan SJ, Jones PW:
Troleandomycin as an oral corticosteroid sparing agent in stable
asthma. Cochrane Database of Systematic Reviews 2000, CD002987.
103. Davies H, Olson L, Gibson P: Methotrexate as a steroid sparing agent for
asthma in adults. Cochrane Database of Systematic Reviews 1998,
CD000391.
104. Hayashi K, Yanagi M, Wood-Baker R, Takamatsu I, Anami K: Oxatomide for
stable asthma in adults and children. Cochrane Database of Systematic
Reviews 2003, CD002179.
105. Petsky HL, Kynaston JA, Turner C, Li AM, Cates CJ, Lasserson TJ, Chang AB:
Tailored interventions based on sputum eosinophils versus clinical
symptoms for asthma in children and adults. Cochrane Database of
Systematic Reviews 2007, CD005603.
106. Dewey A, Dean T, Bara A, Lasserson TJ, Walters EH: Colchicine as an oral
corticosteroid sparing agent for asthma. Cochrane Database of Systematic
Reviews 2003, CD003273.
107. Dewey A, Bara A, Dean T, Walters EH: Dapsone as an oral corticosteroid
sparing agent for asthma. Cochrane Database of Systematic Reviews 2002,
CD003268.
108. Ram FSF, Wedzicha JA: Ambulatory oxygen for chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2008,
CD000238.
109. Jones AP, Rowe BH: Bronchopulmonary hygiene physical therapy for
chronic obstructive pulmonary disease and bronchiectasis. Cochrane
Database of Systematic Reviews 1998, CD000045.
110. Rodrigo G, Pollack C, Rodrigo C, Rowe B, Walters EH: Heliox for treatment
of exacerbations of chronic obstructive pulmonarydisease. Cochrane
Database of Systematic Reviews 2001, CD003571.
111. Nonoyama ML, Brooks D, Lacasse Y, Guyatt GH, Goldstein RS: Oxygen
therapy during exercise training in chronic obstructive pulmonary
disease. Cochrane Database of Systematic Reviews 2007, CD005372.
112. Lacasse Y, Goldstein R, Lasserson TJ, Martin S: Pulmonary rehabilitation for
chronic obstructive pulmonary disease. Cochrane Database of Systematic
Reviews 2006, CD003793.
113. Bradley JM, O’Neill B: Short-term ambulatory oxygen for chronic
obstructive pulmonary disease. Cochrane Database of Systematic Reviews
2005, CD004356.
114. Geddes EL, Reidb WD, Crowe J, O’Brien K, Brooks D: Inspiratory muscle
training in adults with chronic obstructive pulmonary disease: A
systematic review. Respir Med 2005, 99:1440-1458.
115. Geddes EL, O’Brien K, Reid WD, Brooks D, Crowe J: Inspiratory muscle
training in adults with chronic obstructive pulmonary disease: an update
of a systematic review. Respir Med 2008, 102:1715-1729.
116. Lotters FB, van Tol G, Kwakkel R: Gosselink: Effects of controlled
inspiratory muscle training in patients with COPD: a meta-analysis. Eur
Respir J 2002, 20:570-576.
117. Chavannes N, Vollenberg JJ, van Schayck CP, Wouters EFM: Effects of
physical activity in mild to moderate COPD: a systematic review. Br J
Gen Pract 2002, 52:574-578.
118. Rose C, Wallace L, Dickson R, Ayres J, Lehman R, Searle Y, Burge PS: The
most effective psychologically-based treatments to reduce anxiety and
panic in patients with chronic obstructive pulmonary disease (COPD): a
systematic review. Patient Education and Counselling 2002, 47(4):311-318.
119. van ‘t Hul A, Kwakkel G, Gosselink R: The Acute Effects of Noninvasive
Ventilatory Support During Exercise on Exercise Endurance and Dyspnea
in Patients With Chronic Obstructive Pulmonary Disease: A Systematic
Review. J Cardiopulm Rehabil 2002, 22:290-297.
Bailey et al. BMC Pulmonary Medicine 2010, 10:63
http://www.biomedcentral.com/1471-2466/10/63
Page 11 of 13
120. Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE: Systematic
review of the chronic care model in chronic obstructive pulmonary
disease prevention and management. Arch Intern Med 2007,
167(6):551-561.
121. O’Neill B, MacMahon J, Bradley J: Short-burst oxygen therapy in chronic
obstructive pulmonary disease: Evidence-based review. Respir Med 2006,
100:1129-1138.
122. Young J, Fry-Smith A, Hyde C: Lung volume reduction surgery (LVRS) for
chronic obstructive pulmonary disease (COPD) with underlying severe
emphysema. Thorax 1999, 54:779-789.
123. Shoemaker MJ, Donker S, LaPoe A: Inspiratory muscle training in patients
with chronic obstructive pulmonary disease: the state of the evidence.
Cardiopulmon Phy Ther J 2009, 20(3):5-15.
124. Turnock AC, Walters EH, Walters JAE, Wood-Baker R: Action plans for
chronic obstructive pulmonary disease. Cochrane Database of Systematic
Reviews 2005, CD005074.
125. Cranston JM, Crockett AJ, Moss JR, Alpers JH: Domiciliary oxygen for
chronic obstructive pulmonary disease. Cochrane Database of Systematic
Reviews 2005, CD001744.
126. Smith B, Appleton S, Adams R, Southcott A, Ruf R: Home care by outreach
nursing for chronic obstructive pulmonary disease. Cochrane Database of
Systematic Reviews 2001, CD000994.
127. Ram FSF, Wedzicha JA, Wright J, Greenstone M: Hospital at home for
acute exacerbations of chronic obstructive pulmonary disease. Cochrane
Database of Systematic Reviews 2003, CD003573.
128. Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS: Nocturnal non-invasive
positive pressure ventilation for stable chronic obstructive pulmonary
disease. Cochrane Database of Systematic Reviews 2002, CD002878.
129. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS, White J: Nutritional
supplementation for stable chronic obstructive pulmonary disease.
Cochrane Database of Systematic Reviews 2005, CD000998.
130. Ram FSF, Brocklebank DM, Muers M, Wright J, Jones PW: Pressurised
metered-dose inhalers versus all other hand-held inhalers devices to
deliver bronchodilators for chronic obstructive pulmonary disease.
Cochrane Database of Systematic Reviews 2002, CD002170.
131. Salman GF, Mosier MC, Beasley BW, Calkins DR: Rehabilitation for patients
with chronic obstructive pulmonary disease: meta-analysis of
randomised controlled trials. J Gen Intern Med 2003, 18(3):213-221.
132. Monninkhof EM, van der Valk PDLPM, van der Palen J, van
Herwaarden CLA, Partidge MR, Walters EH, Zielhuis GA: Self management
education for chronic obstructive pulmonary disease. Cochrane Database
of Systematic Reviews 2002, CD002990.
133. Austin M, Wood-Baker R: Oxygen therapy in the pre-hospital setting for
acute exacerbations of chronic obstructive pulmonary disease. Cochrane
Database of Systematic Reviews 2006, CD005534.
134. Ram FSF, Picot J, Lightowler J, Wedzicha JA: Non-invasive positive
pressure ventilation for treatment of respiratory failure due to
exacerbations of chronic obstructive pulmonary disease. Cochrane
Database of Systematic Reviews 2004, CD004104.
135. McCrory DC, Brown CD: Anticholinergic bronchodilators versus beta2-
sympathomimetic agents for acute exacerbations of chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2003,
CD003900.
136. Nannini L, Cates CJ, Lasserson TJ, Poole P: Combined corticosteroid and
longacting beta-agonist in one inhaler for chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2004,
CD003794.
137. Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ: Influenza vaccine for
patients with chronic obstructive pulmonary disease. Cochrane Database
of Systematic Reviews 2006, CD002733.
138. Brown CD, McCrory D, White J: Inhaled short-acting beta2-agonists versus
ipratropium for acute exacerbations of chronic obstructive pulmonary
disease. Cochrane Database of Systematic Reviews 2001, CD002984.
139. Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, Cates CJ, Wood-
Baker R: Injectable vaccines for preventing pneumococcal infection in
patients with chronic obstructive pulmonary disease. Cochrane Database
of Systematic Reviews 2006, CD001390.
140. Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, Smith B,
Muhammad J: Ipratropium bromide versus long acting beta-2 agonists
for stable chronic obstructive pulmonary disease. Cochrane Database of
Systematic Reviews 2006, CD006101.
141. Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, Smith B,
Muhammad J: Ipratropium bromide versus short acting beta-2 agonists
for stable chronic obstructive pulmonary disease. Cochrane Database of
Systematic Reviews 2006, CD001387.
142. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM, Cates CJ:
Long-acting beta2-agonists for poorly reversible chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews 2006,
CD001104.
143. Walters JAE, Walters EH, Wood-Baker R: Oral corticosteroids for stable
chronic obstructive pulmonary disease. Cochrane Database of Systematic
Reviews 2005, CD005374.
144. Ram FSF, Jones PW, Castro AA, de Brito Jardim JR, Atallah AN, Lacasse Y,
Mazzini R, Goldstein R, Cendon S: Oral theophylline for chronic
obstructive pulmonary disease. Cochrane Database of Systematic Reviews
2002, CD003902.
145. Sestini P, Renzoni E, Robinson S, Poole P, Ram FSF: Short-acting beta2-
agonists for stable chronic obstructive pulmonary disease. Cochrane
Database of Systematic Reviews 2002, CD001495.
146. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JAE: Systemic
corticosteroids for acute exacerbations of chronic obstructive pulmonary
disease. Cochrane Database of Systematic Reviews 2005, CD001288.
147. Barr RG, Bourbeau J, Camargo CA, Ram FSF: Tiotropium for stable chronic
obstructive pulmonary disease: a meta-analysis. Thorax 2006, 61:854-862,
July 2006.
148. Liesker JJW, Wijkstra PJ, Ten Hacken NHT, Keoter GH, Postma DS,
Kerstjens HAM: A systematic review of the effects of bronchodilators on
exercise capacity in patients with COPD. Chest 2002, 121:597-608.
149. Husereau D, Shukla V, Boucher M, Mensinkai S, Dales R: Long acting β2
agonists for stable chronic obstructive pulmonary disease with poor
reversibility: a systematic review of randomised controlled trials. BMC
Pulm Med 2004, 4:7.
150. Yang IA, Fong KM, Sim EHA, Black PN, Lasserson TJ: Inhaled corticosteroids
for stable chronic obstructive pulmonary disease. Cochrane Database of
Systematic Reviews 2007, CD002991.
151. Barr RG, Rowe BH, Camargo CA Jr: Methylxanthines for exacerbations of
chronic obstructive pulmonary disease. Cochrane Database of Systematic
Reviews 2003, , 2: CD002168, Art. No CD002168.
152. Poole PJ, Black PN: Mucolytic agents for chronic bronchitis or chronic
obstructive pulmonary disease. Cochrane Database of Systematic Reviews
2006, CD001287.
153. Jennings A-L, Davies , Higgins JPT, Gibbs JSR, Broadley KE: A systematic
review of the use of opioids in the management of dyspnoea. Thorax
2002, 57:939-944.
154. French J, Bilton D, Campbell F: Nurse specialist care for Bronchiectasis.
Cochrane Database of Systematic Reviews 2003, CD004359.
155. Bradley J, Moran F, Greenstone M: Physical training for bronchiectasis.
Cochrane Database of Systematic Reviews 2002, CD002166.
156. Wills P, Greenstone M: Inhaled hyperosmolar agents for bronchiectasis
(Review). Cochrane Database of Systematic Reviews 2006.
157. Ram FSF, Wells A, Kolbe J: Inhaled steroids for bronchiectasis. Cochrane
Database of Systematic Reviews 2000, CD000996.
158. Crockett AJ, Cranston JM, Latimer KM, Alpers JH: Mucolytics for
bronchiectasis. Cochrane Database of Systematic Reviews 2001, CD001289.
159. Evans DJ, Bara AI, Greenstone M: Prolonged antibiotics for purulent
bronchiectasis in children and adults. Cochrane Database of Systematic
Reviews 2007, CD001392.
160. Steele K, Lasserson JA, Greenstone M: Oral methylxanthines for
bronchiectasis. Cochrane Database of Systematic Reviews 2000, CD002734.
161. Sheikh A, Nolan D, Greenstone M: Long-acting beta2-agonists for
bronchiectasis. Cochrane Database of Systematic Reviews 2001, CD002155.
162. Franco F, Sheikh A, Greenstone M: Short acting beta2-agonists for
bronchiectasis. Cochrane Database of Systematic Reviews 2003, CD003572.
163. Lasserson TJ, Holt K, Evans D, Milan SJ, Greenstone M: Anticholinergic
therapy for bronchiectasis. Cochrane Database of Systematic Reviews 2001,
CD002163.
164. Corless JA, Warburton CJ: Leukotriene receptor antagonists for non-cystic
fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2000,
CD002174.
165. Lasserson TJ, Holt K, Milan SJ, Greenstone M: Oral steroids for
bronchiectasis (stable and acute exacerbations). Cochrane Database of
Systematic Reviews 2001, CD002162.
Bailey et al. BMC Pulmonary Medicine 2010, 10:63
http://www.biomedcentral.com/1471-2466/10/63
Page 12 of 13
166. Chang CC, Singleton RJ, Morris PS, Chang AB: Pneumococcal vaccines for
children and adults with bronchiectasis. Cochrane Database of Systematic
Reviews 2007, CD006316.
167. Davies HR, Richeldi L, Walters EH: Immunomodulatory agents for
idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews,
D003134 2003, CD003134.
168. Paramothayan S, Lasserson TJ, Walters EH: Immunosuppressive and
cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database of
Systematic Reviews 2006, CD003536.
169. Polosa R, Simidchiev A, Walters EH: Nebulised morphine for severe
interstitial lung disease. Cochrane Database of Systematic Reviews 2002,
CD002872.
170. Paramothayan NS, Lasserson TJ, Jones PW: Corticosteroids for pulmonary
sarcoidosis. Cochrane Database of Systematic Reviews 2005, CD001114.
171. Richeldi L, Davies HR, Ferrara G, Franco F: Corticosteroids for idiopathic
pulmonary fibrosis. Cochrane Database of Systematic Reviews 2003,
CD002880.
172. Staykova T, Black P, Chacko E, Ram FSF, Poole P: Prophylactic antibiotic
therapy for chronic bronchitis. Cochrane Database of Systematic Reviews
2001, CD004105.
173. Spooner CH, Spooner GR, Rowe BH: Mast-cell stabilising agents to
prevent exercise-induced broncho-constriction. Cochrane Database of
Systematic Reviews 2003, CD002307.
174. Spooner CH, Saunders LD, Rowe BH: Nedocromil sodium for preventing
exercise-induced broncho-constriction. Cochrane Database of Systematic
Reviews 2002, CD001183.
175. Kelly K, Spooner CH, Rowe BH: Nedocromil sodium versus sodium
cromoglycate for preventing exercise-induced broncho-constriction in
asthmatics. Cochrane Database of Systematic Reviews 2000, CD002731.
176. Liu C, Chen J: Endothelin receptor antagonists for pulmonary arterial
hypertension. Cochrane Database of Systematic Reviews 2006, CD004434.
177. Paramothayan NS, Lasserson TJ, Wells AU, Walters EH: Prostacyclin for
pulmonary hypertension in adults. Cochrane Database of Systematic
Reviews 2005, CD002994.
178. Kanthapillai P, Lasserson TJ, Walters EH, Sildena l: Sildenafil for pulmonary
hypertension. Cochrane Database of Systematic Reviews 2004, CD003562.
179. Reid WD, Geddes EL, O’Brien K, Brooks D, Crowe J: Effects of inspiratory
muscle training in cystic fibrosis. Clin Rehabil 2008, 22:1003-1013.
180. Asthma UK: Where do we stand? Asthma in the UK today. London,
Asthma UK 2004.
181. Smith NM: The ‘needs of people with asthma’ survey and initial
presentation of the data. Asthma Journal 2000, 5:133-7.
182. World Health Organisation: World Health Statistics. 2008 [http://www.who.
int/whosis/whostat/EN_WHS08_Full.pdf].
183. Lutz S, Norell R, Bertucio C, Kachnic L, Johnson C, Arthur D: Symptom
frequency and severity in patients with metastatic or locally recurrent
lung cancer: a prospective study using the lung cancer symptom scale
in a community hospital. Journal of Palliative Medicine 2001, 4(2):157-65.
184. Booth S, Bausewein C, Higginson I, Moosavi SH: Pharmacological
treatment of refractory breathlessness. Expert Rev Resp Med 2009,
3(1):21-36.
185. Solano JP, Gomes B, Higginson IJ: A Comparison of Symptom Prevalence
in Far Advanced Cancer, AIDS, Heart Disease, Chronic Obstructive
Pulmonary Disease and Renal Disease. J Pain Symptom Manage 2006,
31(1):58-69.
186. Scano G, Stendardi L, Grazzini M: Understanding Dyspnoea by its
language. Eur Respir J 2005, 25:380-385.
187. Coli C, Picariello M, Stendardi L Grazzini M, Binazzi B, Duranti R, Scano G: Is
there a link between the qualitative descriptors and the quantitative
perception of dyspnoea in asthma? Chest 2002, 130:1072-1081.
188. Yorke J, Moosavi SH, Shuldham C, Jones PW: Quantification of dyspnoea
using descriptors: development and initial testing of the Dyspnoea-12.
Thorax 2010, 65:21-26.
189. Bausewein C, Farquhar M, Booth S, Gysels , Higgins IJ: Measurement of
breathlessness in advanced disease: a systematic review. Resp Med 2007,
101:339-410.
190. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA:
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a
measure of disability in patients with chronic obstructive pulmonary
disease. Thorax 1999, 54:581-586.
191. Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR,
Manning HL, Mularski RA, Varkey B, Campbell M, Carter ER, Chiong JR,
Ely EW, Hansen-Flaschen J, O’Donnell DE, Waller A: Consensus statement
on the management of dyspnea in patients with advanced lung or
heart disease. Chest 2010, 137:674-691.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2466/10/63/prepub
doi:10.1186/1471-2466-10-63
Cite this article as: Bailey et al.: An integrative review of systematic
reviews related to the management of breathlessness in respiratory
illnesses. BMC Pulmonary Medicine 2010 10:63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bailey et al. BMC Pulmonary Medicine 2010, 10:63
http://www.biomedcentral.com/1471-2466/10/63
Page 13 of 13
